Treatment interruptions in HIV-infected subjects

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 3, 2006, Pages 502-505

  Bongiovanni, Marco ^a   Casana, Maddalena ^a   Tincati, Camilla ^a   d'Arminio Monforte, Antonella ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

HAART; HIV; STI

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ARTICLE; CD4 LYMPHOCYTE COUNT; CELL LOSS; CELLULAR IMMUNITY; CLINICAL TRIAL; COST OF ILLNESS; DRUG ERUPTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; NONHUMAN; PATIENT MONITORING; RETREATMENT; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN; VIRUS VIRULENCE;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 33747871665     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl268     Document Type: Article

References (29)

1. Palella FJ, Delaney K, Moorman A et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Eng J Med 1998; 338: 853-60.
2. Hoggs RS, O'Shaughnessy MV, Gataric N et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet 1997; 349: 1294.
3. Mocroft A, Vella S, Benfield TL et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1998; 352: 1725-33.
4. DHHS guidelines. Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents. http://aidsinfo.nih.gov (28 September 2005, date last accessed).
5. Papasavvas E, Ortiz GM, Gross R et al. Enhancement of human immunodeficiency virus type-1 specific CD4 and CD8 T cells responses in chronically infected persons after temporary treatment interruption. J Infect Dis 2000; 182: 766-75.
6. Garcia F, Montserrat P, Ortiz GM et al. The virological and immunological consequences of structured treatment interruptions in chronic HIV-1 infection. AIDS 2002; 15 Suppl: F29-40.
7. Miller V. Structured treatment interruptions in antiretroviral management of HIV-1. Curr Opin Infect Dis 2001; 14: 29-37.
8. Deeks SG, Wrin T, Liegler T et al. Virological and immunological consequences of discontinuing combination antiretroviral-drug therapy in HIV infected patients with detectable viremia. N Engl J Med 2001; 344: 472-80.
9. Lawrence J, Mayers DL, Hullsiek KH et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 2003; 349: 837-46.
10. Rosemberg ES, Altfield M, Poon SH et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000; 407: 523-6.
11. Hatano H, Vogel S, Yoder C et al. HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression. AIDS 2000; 14: 1357-63.
12. Desquilbet L, Goujard C, Rouzioux C et al. Does transient HAART during primary HIV-1 infection lower the virological set-point? AIDS 2004; 18: 2361-9.
13. Lisziewicz J, Rosemberg E, Lieberman J et al. Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med 1999; 340: 1683-4.
14. Ortiz GM, Nixon DF, Trkola A et al. HIV-1 specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J Clin Invest 1999; 104: R13-8.
15. Altfeld M, Rosemberg ES, Eldridge RL et al. Increase in breadth and frequency of CTL responses following structured therapy interruptions in individuals treated with HAART during acute HIV-1 infection. In: Programs and Abstracts of the Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, USA, 2000. Abstract 357. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
16. Pellegrin I, Thiebaut R, Blanco P et al. Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and >400 CD4+ cells/μl? Impact on immunovirological parameters. J Med Virol 2005; 77: 164-72.
17. 6 cells/I. AIDS 2005; 19: 287-94.
18. d'Arminio Monforte A, Cozzi-Lepri A, Phillips A et al. Interruption of highly active antiretroviral therapy in HIV clinical practice. J Acquir Immune Defic Syndr 2005; 38: 407-16.
19. Taffe P, Rickembach M, Hirschel B et al. Impact of occasional short interruptions of HAART on the progression of HIV infection: Results from a cohort study. AIDS 2002; 16: 747-55.
20. Barreiro P, de Mendoza C, Gonzalez-Lahoz J et al. Superiority of protease inhibitors over nonnucleoside reverse-transcriptase inhibitors when highly active antiretroviral therapy is resumed after treatment interruption. Clin Infect Dis 2005; 41: 897-900.
21. Arnedo-Valero M, Garcia F, Gil C et al. Risk of selecting de novo drug-resistance mutations during structured treatment interruptions in patients with chronic HIV infection. Clin Inf Dis 2005; 41: 883-90.
22. Nuesch R, Ananworanich J, Sirivichayakul S et al. Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment. Clin Infect Dis 2005; 40: 728-34.
23. Ananworanich J, Nuesch R, LeBraz M et al. Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. AIDS 2003; 17: F33-7.
24. 3. In: Programs and Abstracts of the Thirteenth Conference on Retroviruses and Opportunistic Infections, Denver, USA, 2006. Abstract 101. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
25. Ananworanich J, Gayet-Ageron A, Le Braz M et al. CD4-guided scheduled treatments interruptions compared to continuous therapy: Results of the STACCATO trial. In: Programs and Abstracts of the Thirteenth Conference on Retroviruses and Opportunistic Infections, Denver, USA, 2006. Abstract 102. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
26. Palmisano L, Giuliano M, Bucciardini R et al. Final results of a randomized, controlled trial of structured treatment interruptions vs continuous HAART in chronic HIV-infected subjects with persistent suppression of viral replication. In: Programs and Abstracts of the Thirteenth Conference on Retroviruses and Opportunistic Infections, Denver, USA, 2006. Abstract 103. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
27. Daar ES, Bai J, Hausner MA et al. Acute HIV syndrome after discontinuation of antiretroviral therapy in a patient treated before seroconversion. Ann Intern Med 1998; 128: 827-9.
28. Delaugerre C, Peytavin G, Dominguez S et al. Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097). J Med Virol 2005; 77: 345-50.
29. Katlama C, Dominguez S, Gourlain K et al. Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: A randomized controlled trial (ANRS 097). AIDS 2004; 18: 217-26.